Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kabir A. Khan

Pre- And Post-Operative Anti-Pd-L1 Plus Anti-Angiogenic Therapies in Mouse Breast or Renal Cancer Models of Micro- Or Macro-Metastatic Disease

British Journal of Cancer

Cancer Research

Oncology

2018

English

Anti-Angiogenic Alternatives to VEGF Blockade

Clinical and Experimental Metastasis

English

Related publications

Avelumab, an Anti-Pd-L1 Antibody, in Patients With Locally Advanced or Metastatic Breast Cancer: A Phase 1b JAVELIN Solid Tumor Study

Breast Cancer Research and Treatment

Cancer Research

Oncology

2017

English

Anti‐angiogenic Therapies for Gastric Cancer

Asia-Pacific Journal of Clinical Oncology

Medicine

Oncology

2019

English

Impact of Glucocorticoids on the Gut Microbiome With or Without Anti-Pd-L1

International Journal of Radiation Oncology Biology Physics

English

Commentary: Anti-Fibrotic Agents in the Post-Operative Period: Friends or Foes?

Journal of Thoracic and Cardiovascular Surgery

Respiratory Medicine

Pulmonary

Cardiovascular Medicine

Surgery

Cardiology

2019

English

Poor Outcome With Anti-Programmed Death-Ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-Sensitive Mouse Models

Journal for ImmunoTherapy of Cancer

English

Patterns of Failure in Patients With Locally Advanced Rectal Cancer Receiving Pre-Operative or Post-Operative Chemoradiotherapy

English

The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis

English

Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer

Journal of Cancer

Oncology

2020

English

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment

International Journal of Clinical Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kabir A. Khan

Pre- And Post-Operative Anti-Pd-L1 Plus Anti-Angiogenic Therapies in Mouse Breast or Renal Cancer Models of Micro- Or Macro-Metastatic Disease

Anti-Angiogenic Alternatives to VEGF Blockade

Related publications

Avelumab, an Anti-Pd-L1 Antibody, in Patients With Locally Advanced or Metastatic Breast Cancer: A Phase 1b JAVELIN Solid Tumor Study

Anti‐angiogenic Therapies for Gastric Cancer

Impact of Glucocorticoids on the Gut Microbiome With or Without Anti-Pd-L1

Commentary: Anti-Fibrotic Agents in the Post-Operative Period: Friends or Foes?

Poor Outcome With Anti-Programmed Death-Ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-Sensitive Mouse Models

Patterns of Failure in Patients With Locally Advanced Rectal Cancer Receiving Pre-Operative or Post-Operative Chemoradiotherapy

The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis

Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment